BioSpace News Archive

The not-for-profit community medical center is partnering with Glytec to facilitate standardization of best practices in diabetes therapy management.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its second quarter 2019 financial results after the market closes on Tuesday, August 13, 2019.

Codiak BioSciences, Inc., a company pioneering exosomes as a new class of biologic medicines, today announced that it has expanded its executive leadership team to support the continued advancement of its novel precision exosome therapeutics pipeline.

Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial matching, announces today its newly developed “Hub” aimed to build strategic partnerships with some of the most prominent Just-In-Time (JIT) vendors and provider clinical research teams, looking to facilitate the largest JIT oncology clinical trial network in the world.

XLerateHealth (XLH), an award-winning healthcare accelerator based in Louisville, KY, today announced the selection of nine startup companies to join its 2019 Louisville accelerator cohort.

Cannara Biotech (OTCQB: LOVFF) (CSE: LOVE), based in Montreal, Canada, is focused on the production and sale of premium cannabis and cannabis-infused products for the Canadian and international markets, today announced that Lennie Ryer, Cannara Biotech’s Chief Financial Officer, will present live at VirtualInvestorConferences.com on August 1.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the European Commission (EC), based on a favorable recommendation from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation (ODD) to mavorixafor (X4P-001) for the treatment of WHIM

Supplemental Health Care (SHC), a leading healthcare staffing firm in the United States, announced today the company closed its fiscal year 2019 with its highest talent satisfaction ratings yet

The rise in breast cancer cases across the world, especially in the Americas and Europe, have increased the need to conduct breast cancer screening.

In the Type B meeting, the FDA provided guidance on various design aspects of Bexion’s proposed Phase 2 clinical trial.